Literature DB >> 12883672

Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue.

Koh-Ichi Nakashiro1, Yoshiki Hayashi, Ryoichi Oyasu.   

Abstract

Hepatocyte growth factor (HGF) has been proposed to be an autocrine/paracrine growth factor for carcinomas of various organs. We recently demonstrated that HGF produced by prostate-derived stromal cells was a paracrine growth factor that stimulated the growth of androgen-independent prostate cancer cells in vitro and in vivo. To assess possible involvement of HGF in prostate cancer, we examined the immunohistochemical expression and localization of HGF and c-Met/HGF receptor in benign and malignant human prostate tissues. In benign glands, columnar cells generally were negative for c-Met, but basal cells were stained uniformly at a high level. In high-grade prostatic intraepithelial neoplasia (PIN) and carcinoma, more than 50% of these foci were stained uniformly. There was no difference in the frequency of positively stained cells by Gleason score. The prostate stroma stained diffusely for HGF, and the staining intensity varied depending upon the amounts of smooth-muscle cells that were stained more intensely than the connective-tissue matrix. A great majority of benign columnar cells were negative for HGF whereas high-grade PIN and carcinoma foci stained focally for HGF. Hormonal ablation therapy prior to prostatectomy did not seem to alter the expression of HGF/c-Met in carcinoma cells. These results indicate that, as the degree of neoplasia progresses, epithelial cells begin to express c-Met protein, that PIN and carcinoma may have developed a c-Met-HGF paracrine loop with the stroma, and that in some carcinoma foci an autocrine loop may operate with HGF expressed by carcinoma cells themselves.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883672

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas.

Authors:  Lubin Qiu; Dongsheng He; Xiang Fan; Zhi Li; Chuangxin Liao; Yonghong Zhu; Haijun Wang
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

2.  High-grade prostatic intraepithelial neoplasia.

Authors:  David G Bostwick; Lina Liu; Michael K Brawer; Junqi Qian
Journal:  Rev Urol       Date:  2004

3.  Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.

Authors:  Sean J Gerrin; Adam G Sowalsky; Steven P Balk; Huihui Ye
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.104

4.  The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer.

Authors:  Anita Hryniewicz-Jankowska; Katarzyna Augoff; Aleksander F Sikorski
Journal:  Exp Biol Med (Maywood)       Date:  2019-10

5.  Prostatic intraepithelial neoplasia: an overview.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2005

6.  Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells.

Authors:  Dan Yue; Yong Wang; Ping Ma; Yin-Yan Li; Hong Chen; Ping Wang; Chang-Shan Ren
Journal:  Asian J Androl       Date:  2010-04-19       Impact factor: 3.285

Review 7.  MET and VEGF: synergistic targets in castration-resistant prostate cancer.

Authors:  D T Aftab; D M McDonald
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

8.  Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.

Authors:  Wenbin Kuang; Qiuchan Deng; Chuntao Deng; Wensheng Li; Shaowei Shu; Meirong Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

9.  Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.

Authors:  Koh-Ichi Nakashiro; Shingo Hara; Yuji Shinohara; Miho Oyasu; Hitoshi Kawamata; Satoru Shintani; Hiroyuki Hamakawa; Ryoichi Oyasu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.

Authors:  Jung-Jin Park; Yeung Bae Jin; Yoon-Jin Lee; Jae-Seon Lee; Yun-Sil Lee; Young-Gyu Ko; Minyoung Lee
Journal:  BMC Cancer       Date:  2012-03-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.